Novavax Reports Q3 2026 Revenue of $68.3 Million and Raises Annual Guidance
Novavax (NVAX) reported third-quarter revenue of $68.3 million, marking a significant improvement in net loss to $31.4 million compared to a $202.4 million loss in the prior year. While total revenue saw a decline due to reduced R&D reimbursements from Sanofi as clinical support nears completion, product sales surged 91% to $25.7 million, driven by supply sales of Nuvaxovid and Matrix-M to licensed partners. The company raised its adjusted total revenue guidance to a range of $385 million to $415 million, up from the previous estimate of $235 million to $275 million. Management highlighted a strong cash position of $676 million, which they expect will support operations into 2029. Future profitability remains heavily contingent on Sanofi's commercial launch of its combination influenza-COVID-19 vaccine.
Topics: guidance upgrade net loss improvement R&D reimbursement revenue vaccine sales